درباره این اپیزود
For decades, psychiatry has relied on symptom-based diagnosis and trial-and-error treatment, but precision medicine is set to transform mental health care by using objective biological measures—such as EEG, sleep and circadian rhythm data, and cognitive testing—with AI-driven analysis to match patients with the therapies most likely to work for them. In this episode of Behind the Breakthroughs, Alto Neuroscience founder and CEO Amit Etkin explains how biomarker-guided drug development and biologically defined patient populations could make precision psychiatry routine, improving outcomes and changing how psychiatric disorders are diagnosed and treated.
Produced and hosted by Jonathan D. Grinstein, PhD
Audio mixed and mastered by Erick Ziegler
Brought to you by Inside Precision Medicine (SAGE Publishing)
Hosted on Acast. See acast.com/privacy for more information.
